BioSpace News Archive

Magellan Health, Inc. (NASDAQ: MGLN) today announced that it will report its earnings for the fourth quarter and full year ended on December 31, 2019 at approximately 6:30 a.m. Eastern on Friday, February 28, 2020. At 8:30 a.m.

Avivagen Inc. (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, promote general health and performance, has entered into a binding distribution agreement with Manila-based INPHILCO, Inc. that will see the company become a new, key distribution partner for OxC-betaTM Livestock in the rapidly growing Philippines market.

TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that management will participate in two upcoming conferences in February.

FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2019 financial results after market close on Monday, March 2, 2020. FibroGen will also conduct a conference call on that day at 5:00 p.m. (2:00 p.m. PT)

PureTech Health plc announced that Daphne Zohar, founder and chief executive officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York on Tuesday, February 25, at 9:00 AM EST.

Aridis Pharmaceuticals, Inc. announced that it will host an Investor Day on Thursday, March 12th, 2020 in New York City from 12:00PM-2:00PM EST.

Bruker Corporation announced certain preliminary operating results for its fourth quarter and fiscal year ended December 31, 2019.

Brickell Biotech, Inc. and its subsidiary (collectively, “Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced Brickell, and Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor (collectively, “Bodor”), entered into a settlement agreement and an amended license agreement.

Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has received CE Mark approval for its lead product, the Contour Neurovascular System™, for the treatment of intracranial aneurysms.

Medtronic plc announced financial results for its third quarter of fiscal year 2020, which ended January 24, 2020.